Patent: 6,537,520
✉ Email this page to a colleague
Summary for Patent: 6,537,520
Title: | Pharmaceuticals for the imaging of angiogenic disorders |
Abstract: | The present invention describes novel compounds of the formula: useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent. |
Inventor(s): | Rajopadhye; Milind (Westford, MA), Edwards; D. Scott (Burlington, MA), Barrett; John A. (Groton, MA), Carpenter, Jr.; Alan P. (Carlisle, MA), Harris; Thomas D. (Samel, NH), Heminway; Stuart J. (Lowell, MA), Liu; Shuang (Chelmsford, MA), Singh; Prahlad R. (Arlington, MA) |
Assignee: | Bristol-Myers Squibb Pharma Company (Princeton, NJ) |
Application Number: | 09/599,295 |
Patent Claims: | see list of patent claims |
Details for Patent 6,537,520
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eisai, Incorporated | ONTAK | denileukin diftitox | Injection | 103767 | 02/05/1999 | ⤷ Try a Trial | 2018-03-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |